Imidazopyrimidines, Potent Inhibitors of P38 MAP Kinase

Authors

Kenneth C. Rupert, Merck
James R. Henry, Johnson & Johnson
John H. Dodd, Bristol-Myers SquibbFollow
Scott A. Wadsworth, Envigo PLCFollow
Druie E. Cavender, Newberry CollegeFollow
Gilbert C. Olini, Johnson & JohnsonFollow
Bohumila Fahmy, Johnson & JohnsonFollow
John Siekierka, Montclair State UniversityFollow

Document Type

Article

Publication Date

2-1-2003

Journal / Book Title

Bioorganic & Medicinal Chemistry Letters

Abstract

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

DOI

10.1016/S0960-894X(02)01020-X

Montclair State University Digital Commons Citation

Rupert, Kenneth C.; Henry, James R.; Dodd, John H.; Wadsworth, Scott A.; Cavender, Druie E.; Olini, Gilbert C.; Fahmy, Bohumila; and Siekierka, John, "Imidazopyrimidines, Potent Inhibitors of P38 MAP Kinase" (2003). Department of Chemistry and Biochemistry Faculty Scholarship and Creative Works. 358.
https://digitalcommons.montclair.edu/chem-biochem-facpubs/358